Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 241
Filter
1.
J Drugs Dermatol ; 23(2): 29-37, 2024 Feb 01.
Article in English | MEDLINE | ID: mdl-38306143

ABSTRACT

BACKGROUND: Sebaceous hyperplasia (SH) is a common, benign but cosmetically bothersome skin condition preferentially affecting older adults. Despite multiple treatment options, there is no universally accepted first-line treatment for SH nor standard pricing for said approaches.  Methods: A survey aimed at evaluating treatment approaches and their respective costs was disseminated on the Orlando Dermatology Aesthetic and Clinical Conference email listserv.  Results: Out of 224 dermatologists who participated in the survey (response rate 9.2%), most treated patients with SH (95.98%). In-office procedures were used more than pharmacologic treatments (P=<0.05). Treatments most used by respondents included electrodesiccation (ED; 83.9%), cryosurgery (35.3%), oral isotretinoin (32.6%), and carbon dioxide (CO2) laser (19.2%). Cryosurgery and ED priced between <$200 to $400. Most reported 1 to 2 sessions to achieve lesion clearance for ED, CO2 laser, and cryosurgery. Twenty-one percent reported 3-4 sessions with cryosurgery. Chemical peels, diode lasers, and photodynamic therapy required between 2-4 sessions. Respondents indicated lesions were most unlikely to recur with ED and CO2 laser. Most dermatologists (86.39%) agreed or strongly agreed that they were exposed to new treatments methods for SH through this survey and 86.49% of dermatologists were interested in learning about treatments employed by others. CONCLUSION: SH is a common issue that presents in the dermatologist's office. These data highlight the perception that ED is the most common approach employed, associated with lower costs, and requiring fewer sessions to achieve resolution. More data is needed and wanted to better determine best practices for the management of SH.J Drugs Dermatol. 2024;23(2):29-37.  doi:10.36849/JDD.7734.


Subject(s)
Photochemotherapy , Sebaceous Gland Diseases , Humans , Aged , Hyperplasia/therapy , Sebaceous Gland Diseases/pathology , Photochemotherapy/methods , Dermabrasion , Surveys and Questionnaires
2.
Am J Surg ; 223(1): 94-100, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34325908

ABSTRACT

INTRODUCTION: Lobular carcinoma in situ (LCIS), atypical ductal and lobular hyperplasia (AH) increase breast cancer risk. We examined risk management recommendations (RMR) and acceptance in AH/LCIS. METHODS: All patients with AH/LCIS on core needle biopsy from 2013 to 2016 at our institution were identified; cancer patients were excluded. Univariate and multivariate analysis examined factors associated with management. RESULTS: 98 % of patients were evaluated by breast surgeons and 53 % underwent risk model calculation (RC). 77 % had new RMR. RMR of MRI screening (MRI), genetic counselling (GC) and medical oncology (MO) referral were 41 %, 18 %, 77 %, respectively. MRI screening was more likely recommended in those with strong family history (p = 0.01), and high RC (p < 0.001). Uptake of at least one RMR did not occur in 84 % of patients. Use of RC correlated with MO acceptance (p = 0.049). CONCLUSIONS: Diagnosis of atypia has the potential to change risk management for most, however only 16 % of patients accepted all RMR.


Subject(s)
Breast Carcinoma In Situ/diagnosis , Breast Neoplasms/prevention & control , Breast/pathology , Patient Acceptance of Health Care/statistics & numerical data , Risk Reduction Behavior , Adult , Breast/diagnostic imaging , Breast/surgery , Breast Carcinoma In Situ/epidemiology , Breast Carcinoma In Situ/pathology , Breast Carcinoma In Situ/therapy , Breast Neoplasms/epidemiology , Breast Neoplasms/pathology , Female , Genetic Counseling/statistics & numerical data , Humans , Hyperplasia/diagnosis , Hyperplasia/epidemiology , Hyperplasia/pathology , Hyperplasia/therapy , Magnetic Resonance Imaging/statistics & numerical data , Mass Screening/statistics & numerical data , Middle Aged , Risk Assessment/statistics & numerical data
4.
Medicine (Baltimore) ; 100(13): e24875, 2021 Apr 02.
Article in English | MEDLINE | ID: mdl-33787577

ABSTRACT

BACKGROUND: In recent years, with the accelerated pace of life, diet, environmental problems occur frequently. External factors are easily to cause endocrine disorders and hormone sensitivity of breast tissue, which can lead to mammary hyperplasia. The incidence rate of hyperplasia of mammary glands is increasing year by year, and the age of onset is also getting lower and lower. If not treated in time, there is a crisis of breast cancer.Clinical studies have found that auricular point pressing therapy is widely used in clinical treatment of mammary hyperplasia recently, but the efficacy of massage in the treatment of mammary hyperplasia has not been systematically reviewed. The purpose of this study is to explore the efficacy, safety and effectiveness of auricular point pressing therapy in the treatment of hyperplasia of mammary glands. METHODS: We will search PubMed, Web of Science, Cochrane Library, EMBASE, Wan fang Database, Chinese Scientific Journal Database, CNKI, VIP, and Chinese Biomedical Literature Database. The retrieval date was January 10, 2021. RevMan 5.3 software was used to evaluate the quality and risk of included studies. The efficacy, recurrence rate, and symptom score of breast hyperplasia were analyzed, and the results were observed and measured. RESULTS: This study will be from the clinical efficiency, improvement rate, pain symptoms disappear rate, tumor size improvement rate, and other aspects of the existing evidence for a high quality synthesis, as well as auricular point pressing therapy adverse events. CONCLUSION: the conclusion of this review will provide the basis for judging whether auricular point pressing therapy is safe and effective in the treatment of hyperplasia of mammary glands. ETHICS AND DISSEMINATION: This systematic will evaluate the effectiveness and safety of auricular point pressing therapy in the treatment of hyperplasia of mammary glands. As all data used in this systematic review and meta-analysis have been published, ethical approval is not required for this review. PROTOCOL REGISTRATION NUMBER: INPLASY202110028.


Subject(s)
Acupuncture Points , Breast Diseases/therapy , Mammary Glands, Human/pathology , Massage/methods , Breast Diseases/pathology , Clinical Trials as Topic , Ear Auricle , Female , Humans , Hyperplasia/therapy , Meta-Analysis as Topic , Research Design , Systematic Reviews as Topic , Treatment Outcome
5.
Gynecol Endocrinol ; 37(8): 677-682, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33759685

ABSTRACT

Hyperthecosis is defined as the presence of nests of luteinized theca cells in the ovarian stroma. Persistent testosterone released by ovarian theca cells is unmasked postmenopausally through the loss of granulosa cell-mediated aromatization of testosterone to estradiol. Ovarian hyperthecosis (OH) usually presents with symptoms of hyperandrogenism and is often described as a severe or extreme form of Polycystic Ovary Syndrome (PCOS). Serum testosterone levels in excess of 150 ng/dl (>5.2 nmol/l) are seen in affected patients and this threshold is used to confirm a diagnosis. Treatment of hyperthecosis is multi-faceted. It addresses the attendant hyperandrogenism (hirsutism and virilization) as well as metabolic complications such as obesity and insulin resistance. Ultimately, laparoscopic bilateral salpingo-oophorectomy is definitive treatment. This remains the treatment of choice in postmenopausal women whereas treatment using GnRH agonists may be used in women of reproductive age, especially younger women. Nevertheless, if serum testosterone remains elevated despite several months of therapy with a GnRH agonist, surgery is often required for biopsy sample collection and further definitive therapy. In order to mitigate the common clinical manifestations of hyperandrogenism, anti-androgen therapy (either cyproterone acetate or spironolactone) may be used to suppress the actions of testosterone on tissues. In patients with impaired glucose metabolism and insulin resistance, Metformin should also be considered as part of treatment. Combined, such a treatment regimen will often lead to decreased ovarian androgen secretion.


Subject(s)
Hyperandrogenism/etiology , Ovarian Diseases/complications , Ovary/pathology , Stromal Cells/pathology , Diagnosis, Differential , Female , Humans , Hyperandrogenism/diagnosis , Hyperplasia/complications , Hyperplasia/diagnosis , Hyperplasia/therapy , Magnetic Resonance Imaging , Ovarian Diseases/diagnosis , Ovarian Diseases/pathology , Polycystic Ovary Syndrome/complications , Polycystic Ovary Syndrome/diagnosis , Testosterone/blood , Ultrasonography
6.
Zhen Ci Yan Jiu ; 46(1): 76-83, 2021 Jan 25.
Article in Chinese | MEDLINE | ID: mdl-33559431

ABSTRACT

OBJECTIVE: To analyze the acupoint combination regularities and application characteristics of core acupoints in acupuncture-moxibustion treatment of mammary gland hyperplasia (MGH) by using complex network technology, so as to provide reliable evidence for clinical selection of acupoints and treatment ideas. METHODS: The articles related to acupuncture treatment of MGH published from January of 1981 to May of 2020 were collected from databases as China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform (Wanfang), Chinese Journal of Science and Technology of VIP (VIP), PubMed, the Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science and Ovid database (OVID) according to the set inclusion and exclusion criteria of the present paper and by using keywords of "mammary gland hyperplasia", "mastalgia" or "fibrocystic breast change", "breast cystic hyperplasia ", etc. plus "acupuncture", "moxibustion", etc. Then, a correlative database model was established by using SPSS Modeler 18.0 to analyze their association regularities, followed by conducting a complex network analysis with Gephi 0.9.2 software. RESULTS: A total of 312 eligible articles containing 343 acupoint prescriptions and 113 acupoints were collected. The total frequency of use of the 113 acupoints was 1 998. The association regularity analysis showed a top relativity between Danzhong(CV17) and Zusanli(ST36). The analysis of the complex network topology revealed that CV17, Qimen(LR14), Sanyinjiao(SP6), Taichong(LR3), ST36, Jianjing(GB21), Rugen(ST18), Wuyi(ST15), Neiguan(PC6), Ashi-points, Fenglong (SP40), Guanyuan(CV4), Taixi(KI3), Tianzong(SI11), Ganshu (BL18), and Hegu(LI14) are the core acupoints for treatment of MGH. The principle for composing acupoint prescriptions is mainly the combination of acupoints on the left and right sides, the upper and lower parts, front and back parts of the body, respectively, and those of the outer and inner meridians, and those of the same name meridians and Zangfu-organ syndrome differentiation. The needle-insertion direction is mostly toward the focus. CONCLUSION: The composition of acupoint prescriptions for treating MGH with acupuncture and moxibustion is mainly based on the combination of specific acupoints among which the confluent acupoints are most frequently used, followed by the combination of acupoints distributing at the chest, back, upper and lower limbs, and the local acupoints.


Subject(s)
Acupuncture Therapy , Mammary Glands, Human , Meridians , Moxibustion , Acupuncture Points , China , Humans , Hyperplasia/therapy
7.
Surgery ; 169(1): 94-101, 2021 01.
Article in English | MEDLINE | ID: mdl-32732069

ABSTRACT

BACKGROUND: Tertiary hyperparathyroidism associated with end-stage renal disease is characterized by progression from secondary hyperparathyroidism to an autonomous overproduction of parathyroid hormone that leads to adverse health outcomes. Rates of parathyroidectomy (PTX) have decreased with the use of calcimimetics. Optimal timing of PTX in relation to kidney transplant remains controversial. We aimed to identify the most cost-effective strategy for patients with tertiary hyperparathyroidism undergoing kidney transplant. METHODS: We constructed a patient level state transition microsimulation to compare 3 management schemes: cinacalcet with kidney transplant, cinacalcet with PTX before kidney transplant, or cinacalcet with PTX after kidney transplant. Our base case was a 55-year-old on dialysis with tertiary hyperparathyroidism awaiting kidney transplant. Outcomes, including quality-adjusted life years, surgical complications, and mortality, were extracted from the literature, and costs were estimated using Medicare reimbursement data. RESULTS: Our base case analysis demonstrated that cinacalcet with PTX before kidney transplant was dominant, with a lesser cost of $399,287 and greater quality-adjusted life years of 10.3 vs $497,813 for cinacalcet with PTX after kidney transplant (quality-adjusted life years 9.4) and $643,929 for cinacalcet with kidney transplant (quality-adjusted life years 7.4). CONCLUSION: Cinacalcet alone with kidney transplant is the least cost-effective strategy. Patients with end-stage renal disease-related tertiary hyperparathyroidism should be referred for PTX, and it is most cost-effective if performed prior to kidney transplant.


Subject(s)
Cost-Benefit Analysis/statistics & numerical data , Hyperparathyroidism, Secondary/therapy , Kidney Failure, Chronic/therapy , Parathyroid Hormone/blood , Parathyroidectomy/statistics & numerical data , Calcimimetic Agents/economics , Calcimimetic Agents/therapeutic use , Calcium/blood , Calcium/metabolism , Cinacalcet/economics , Cinacalcet/therapeutic use , Computer Simulation , Disease Progression , Humans , Hyperparathyroidism, Secondary/blood , Hyperparathyroidism, Secondary/etiology , Hyperparathyroidism, Secondary/pathology , Hyperplasia/blood , Hyperplasia/etiology , Hyperplasia/pathology , Hyperplasia/therapy , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/physiopathology , Medicare/economics , Medicare/statistics & numerical data , Middle Aged , Parathyroid Glands/pathology , Parathyroid Glands/surgery , Parathyroid Hormone/metabolism , Parathyroidectomy/economics , Quality-Adjusted Life Years , Renal Dialysis , Renal Elimination/physiology , Time-to-Treatment/economics , Time-to-Treatment/statistics & numerical data , United States
8.
Medicine (Baltimore) ; 99(52): e23601, 2020 Dec 24.
Article in English | MEDLINE | ID: mdl-33350735

ABSTRACT

BACKGROUND: With the accelerated pace of life, the problems of residence, diet, and environment have occurred frequently in recent years. External factors are easily to cause endocrine disorders and hormone sensitivity of breast tissue, which can lead to mammary hyperplasia. The incidence rate of hyperplasia of mammary glands is increasing year by year, and the age of onset is also getting lower and lower. If not treated in time, there is a crisis of breast cancer.Clinical studies have found that massage is widely used in clinical treatment of mammary hyperplasia recently, but the efficacy of massage in the treatment of mammary hyperplasia has not been systematically reviewed. The purpose of this study is to explore the efficacy, safety and effectiveness of massage in the treatment of hyperplasia of mammary glands. METHODS: We will search PubMed, Cochrane Central Register of controlled trials (central), ScienceNet, EMBASE, CBM, CNKI, VIP and Wanfang databases. The retrieval date was October 20, 2020. RevMan 5.3 software was used to evaluate the quality and risk of included studies. The efficacy, recurrence rate, and symptom score of breast hyperplasia were analyzed, and the results were observed and measured. RESULTS: This study will be from the clinical efficiency, improvement rate, pain symptoms disappear rate, tumor size improvement rate and other aspects of the existing evidence for a high quality synthesis, as well as massage adverse events. CONCLUSION: the conclusion of this review will provide the basis for judging whether massage is safe and effective in the treatment of hyperplasia of mammary glands. ETHICS AND DISSEMINATION: This systematic will evaluate the effectiveness and safety of massage in the treatment of hyperplasia of mammary glands. As all data used in this systematic review and meta-analysis have been published, ethical approval is not required for this review. PROTOCOL REGISTRATION NUMBER: INPLASY2020100066.


Subject(s)
Mammary Glands, Human/pathology , Massage , Meta-Analysis as Topic , Research Design , Systematic Reviews as Topic/methods , Female , Humans , Hyperplasia/therapy
9.
Medicine (Baltimore) ; 99(36): e22055, 2020 Sep 04.
Article in English | MEDLINE | ID: mdl-32899068

ABSTRACT

BACKGROUND: Multiple randomized controlled trials have shown that acupuncture (ACU) work well in the treating mammary gland hyperplasia, which has been widely used in hospitals of China. Although the choices of ACU treatments varies in practice, most are based on experience or preference. Therefore, we outline a plan to assess and rank the efficacy of the various ACU methods to formulate a prioritized regimen for mammary gland hyperplasia in ACU therapy. METHODS: We will make a comprehensive retrieval in 7 databases as following: PubMed, Embase, Cochrane Library, China BioMedical Literature, China National Knowledge Infrastructure, Chinese Scientific Journals Database, and Wanfang database. The time is limited from the construction of the library to June 2020. We will evaluate the quality and the evidence of the included randomized controlled trials by the risk of bias tool and grading of recommendations assessment, development and evaluation, respectively. Bayesian network meta-analysis will be conducted using Stata16.0 and WinBUGS V.1.4.3. RESULTS: The results of this study will be published in a peer-reviewed journal. CONCLUSIONS: Our study is expected to provide high-quality, evidence-based recommendations on further treatment of MGH for clinicians. REGISTRATION: PROSPERO (registration number CRD42020158743).


Subject(s)
Acupuncture Therapy/methods , Hyperplasia/therapy , Mammary Glands, Human/pathology , Adult , Bayes Theorem , China/epidemiology , Clinical Protocols , Female , Humans , Middle Aged , Network Meta-Analysis , Randomized Controlled Trials as Topic , Treatment Outcome
10.
Neumol. pediátr. (En línea) ; 15(3): 402-405, sept. 2020. tab, ilus
Article in Spanish | LILACS | ID: biblio-1127612

ABSTRACT

A clinical case of Neuroendocrine Cell Hyperplasia is presented with a bibliographic review. An infant patient with respiratory distress syndrome, characterized by nasal flaring, retractions, and tachypnea with temporary resolution with the use of bronchodilators. However, the patient requires oxygen. With complementary examinations (negative viral panel twice) and epidemiology it is classified as a viral Bronchiolitis. Without improvement, extrapulmonar pathologies were suspected, discarding hearth disease, epilepsy, pathological gastroesophageal reflux. New tests were performed to rule out other pathologies, including immunological disorders. Those results were normal, so a high-resolution chest tomography was done which allowed the diagnosis of Neuroendocrine Cell Hyperplasia. During the follow up the child had improved and required oxygen until he was two years old. Neuroendocrine Cell Hyperplasia belongs to a huge group of less common interstitial disorders, which diagnosis is clinical and radiological. It can easily be confused with common respiratory disorders. For this reason, it is important to know about this disease to make an early diagnosis. Most of the cases had a gradual (months to years) improvement.


Se presenta un caso clínico de Hiperplasia de Células Neuroendocrinas y la revisión de la literatura. Paciente lactante menor con cuadro de dificultad respiratoria, caracterizado por aleteo nasal, retracciones y taquipnea persistente acompañada de desaturación. Sin adecuada respuesta al uso de broncodilatadores. Por exámenes complementarios, panel viral negativo en dos ocasiones y epidemiología, se le diagnostica una bronquiolitis viral. Por no presentar mejoría se completan estudios, descartándose neumonía atípica, cardiopatía, epilepsia, reflujo gastroesofágico patológico y compromiso inmunológico. El diagnóstico fue determinado en base a la clínica, junto con imágenes en vidrio esmerilado característicos en lóbulo medio y língula. En su seguimiento mejora paulatinamente, requiriendo soporte de oxígeno hasta los dos años. La Hiperplasia de Células Neuroendocrinas es una patología intersticial pulmonar poco frecuente, cuyo diagnóstico es clínico y radiológico. Puede ser fácilmente confundida con desórdenes respiratorios comunes, por lo que es importante sospecharla para realizar un diagnóstico precoz. La mayor parte de los casos evolucionan con declinación de los síntomas, mejorando espontáneamente en meses o en los primeros años de vida.


Subject(s)
Humans , Infant , Lung Diseases, Interstitial/diagnosis , Neuroendocrine Cells/pathology , Hyperplasia/diagnosis , Oxygen/therapeutic use , Lung Diseases, Interstitial/therapy , Tachypnea/etiology , Hyperplasia/therapy
11.
Medicine (Baltimore) ; 99(29): e21103, 2020 Jul 17.
Article in English | MEDLINE | ID: mdl-32702858

ABSTRACT

RATIONALE: Lymphadenectomy for tongue cancer in the neck region is often accompanied by local impaired mobility, gland damage, difficult in swallowing, and postoperative complication and seriously affects patients life quality. We reported a case of subcutaneous adhesions and scar hyperplasia in the neck region after lymphadenectomy for tongue lesions accompanied by impaired neck mobility and difficult in swallowing was treated using Fu's subcutaneous needling (FSN) treatment. PATIENT CONCERNS: A 55-year-old male with tongue cancer received surgical intervention with lymphadenectomy 8 years ago was revealed a 15 cm-long curved surgical incision in the neck region and surrounded by numerous scar tissues. DIAGNOSIS: Post-operation subcutaneous adhesions and scar hyperplasia in the neck region after lymphadenectomy was diagnosed. INTERVENTIONS: FSN treatment was performed 2 to 3 times per week for 1 month to sway the affected tightened muscle and dissociate the superficial fascia beneath the scar resulted in a considerable improvement in neck movement. OUTCOMES: The Vancouver Scar Scale (VSS) was as follows: color (M) - 1; vascular distribution (V) - 0, thickness (H) - 2, and flexibility (P) - 4, with a total of 7 points before FSN treatment. The VSS after 1 month of FSN treatment was as follows: M1, V0, H2, and P2, with a total of 5 points. Neck mobility in different directions, i.e., stretching to the back of the neck and laterally bending the neck to the left and/or right side, was improved (P < .05). LESSONS: At present, treatment of chronic scar hyperplasia has certain side effects and limitations. FSN is safe and convenient, with minimal destruction of the superficial fascia, having evident effects of dissociating tissue adhesion under scars and compensating for deficiencies in scar hyperplasia treatment. It can provide new ideas for future treatments.


Subject(s)
Hyperplasia/therapy , Neck/abnormalities , Subcutaneous Tissue/abnormalities , Tissue Adhesions/therapy , Humans , Hyperplasia/pathology , Hyperplasia/physiopathology , Male , Middle Aged , Neck/physiopathology , Subcutaneous Tissue/pathology , Subcutaneous Tissue/physiopathology , Tissue Adhesions/pathology , Tissue Adhesions/physiopathology , Tongue Neoplasms/complications , Tongue Neoplasms/physiopathology , Tongue Neoplasms/surgery
12.
Medicine (Baltimore) ; 99(21): e20300, 2020 May 22.
Article in English | MEDLINE | ID: mdl-32481314

ABSTRACT

To study the effects of Tui Na therapy on patients with mammary gland hyperplasia.A total of 68 female patients with mammary gland hyperplasia were included in this retrospective study from May 2016 to May 2017 and assigned into control group (N = 34) treated with Rupixiao only (a proprietary Chinese medicine) or Tui Na group (N = 34) treated with Tui Na (Chinese massage) combined with Rupixiao. The pain intensity (visual analogous scale, VAS) and serum levels of luteinizing hormone (LH), estradiol (E2), prolactin (PRL), and progesterone (P) were examined before and after the treatment.The efficacies were 94.1% (32/34) in the Tui Na group and 76.5% (26/34) in the control group (P = .04). After treatment, VAS in Tui Na groups was significantly lower than that in control group (2.1 ±â€Š1.1 vs 3.1 ±â€Š1.1, P < .05). After follow-up for five months, the recurrence rates were 12.5% (4/32) in the Tui Na group and 23.1% (6/26) in the control group (P = .01). The levels of all 4 hormones in the Tui Na group increased significantly after treatment. In control group, only LH and E2 levels were significantly increased after treatment.In patients with mammary gland hyperplasia, Tui Na combined with Rupixiao could improve clinical symptoms, regulate sex hormone levels, and decrease the recurrence rate than Rupixiao alone. Our finding suggests that Tui Na can be potentially used for the treatment of mammary gland hyperplasia.


Subject(s)
Acupressure/methods , Breast Diseases/therapy , Massage/methods , Plants, Medicinal , Breast Diseases/blood , Female , Follow-Up Studies , Gonadal Steroid Hormones/blood , Humans , Hyperplasia/blood , Hyperplasia/therapy , Retrospective Studies , Treatment Outcome , Young Adult
13.
Acta pediatr. esp ; 78(3/4): e183-e185, mar.-abr. 2020. ilus
Article in Spanish | IBECS | ID: ibc-202528

ABSTRACT

La enfermedad pulmonar intersticial (EPI) es una entidad que incluye patologías raras de baja prevalencia, que involucran factores genéticos y ambientales, caracterizados por la remodelación del intersticio y los espacios aéreos pulmonares. La hiperplasia de células neuroendocrinas es una enfermedad rara del pulmón descrita por primera vez en 2005, caracterizada por retracciones de costillas, taquipnea e hipoxemia. El diagnóstico es clínico junto con la imagen de la tomografía computarizada de alta resolución (TACAR), siendo excepcional la necesidad de biopsia pulmonar. El tratamiento es sintomático, con pronóstico incierto, mejorando los síntomas con el tiempo, aunque en ciertas ocasiones pueden persistir durante años


Interstitial lung disease (ILD) is an entity that includes rare pathologies of low prevalence, involving genetic and environmental factors, characterized by the remodeling of the interstitium and lung air spaces. Neuroendocrine cell hyperplasia is a rare disease of the lung described for the first time in 2005, characterized by rib retractions, tachypnea and hypoxemia. The diagnosis is clinical along with the image of the high resolution computerized tomography (HRCT), the need for lung biopsy being exceptional. The treatment is symptomatic, with uncertain prognosis, improving the symptoms over time, although in certain occasions they may persist for years


Subject(s)
Humans , Female , Infant , Hyperplasia/diagnostic imaging , Lung Diseases, Interstitial/diagnostic imaging , Hyperplasia/therapy , Lung Diseases, Interstitial/therapy , Hyperplasia/genetics , Lung Diseases, Interstitial/genetics , Neuroendocrine Cells , Tomography, X-Ray Computed , Radiography, Thoracic , Rare Diseases/diagnosis , Rare Diseases/therapy
15.
J Cosmet Dermatol ; 19(4): 866-868, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31376204

ABSTRACT

The past decade has experienced a surge in the frequency of nonsurgical procedures, including injectables, skin rejuvenation, and nonsurgical fat reduction. Nonsurgical fat reduction methods include cryolipolysis (Coolsculpting), ultrasound (Vaser Shape), laser (Liposonix), and radiofrequency (Vanquish). These methods generally produce good results, with cryolipolysis gaining much popularity over the past few years. Multiple reports of paradoxical adipose hyperplasia have been reported with Coolsculpting, with an incidence of 0.025% to 1%. This entity has never been reported with other methods of nonsurgical fat reduction, including noninvasive radiofrequency (Vanquish). We present a case of paradoxical adipose hyperplasia in a 57-year-old male following treatment with noninvasive radiofrequency (Vanquish) to the abdomen. He was treated with power-assisted liposuction to the abdomen and flanks. This is the first case in the literature of paradoxical adipose hyperplasia in a patient treated with this form of noninvasive fat reduction.


Subject(s)
Body Contouring/adverse effects , Lipectomy , Radiofrequency Therapy/adverse effects , Subcutaneous Fat, Abdominal/pathology , Body Contouring/methods , Cryosurgery/adverse effects , Extracorporeal Shockwave Therapy/adverse effects , Humans , Hyperplasia/etiology , Hyperplasia/therapy , Low-Level Light Therapy/adverse effects , Male , Middle Aged , Subcutaneous Fat, Abdominal/radiation effects , Treatment Outcome
16.
Dermatol Surg ; 46(6): 803-809, 2020 06.
Article in English | MEDLINE | ID: mdl-31592824

ABSTRACT

BACKGROUND: Nanosecond pulsed electric field (nsPEF) technology involves delivery of ultrashort pulses of electrical energy and is a nonthermal, drug-free technology that has demonstrated favorable effects on cellular structures of the dermis and epidermis. OBJECTIVE: Determine the tolerability and effectiveness of nsPEF treatment of sebaceous gland hyperplasia (SGH). METHODS: This study was a prospective, randomized, open-label, multisite, nonsignificant risk trial in which each subject served as their own control. After injection of local anesthetic, high-intensity, ultrashort pulses of electrical energy were used to treat 72 subjects resulting in a total of 222 treated lesions. Subjects returned for 3 to 4 follow-up evaluations with photographs. RESULTS: At the final study visit, 99.6% of treated SGH lesions were rated clear or mostly clear and 79.3% of the subjects were satisfied or mostly satisfied with the outcome. At 60 days after nsPEF treatment, 55% of the lesions were judged to have no hyperpigmentation and 31% exhibited mild post-treatment hyperpigmentation. At the last observation for all lesions, 32% of the 222 lesions were noted as having slight volume loss. CONCLUSION: Nanosecond pulsed electric field procedure is well tolerated and is very effective in the removal of SGHs. TRIAL REGISTRATION: ClinicalTrials.gov NCT03612570.


Subject(s)
Electric Stimulation Therapy/methods , Sebaceous Glands/pathology , Adult , Aged , Electric Stimulation Therapy/adverse effects , Electric Stimulation Therapy/instrumentation , Female , Follow-Up Studies , Humans , Hyperplasia/diagnosis , Hyperplasia/therapy , Male , Middle Aged , Photography , Prospective Studies , Sebaceous Glands/diagnostic imaging , Severity of Illness Index , Treatment Outcome
18.
Article in English | MEDLINE | ID: mdl-30901063

ABSTRACT

INTRODUCTION: Sebaceous hyperplasia (SH) is a common cutaneous disorder associated with cosmetic problems. Some optional treatments and various laser devices have been reported to be effective, but recurrence and cosmetic outcome have not been resolved. METHODS: This interventional study was performed on SH lesions. First, the lesions were treated with a CO2 laser, and then the shrunken lesions were removed with a fine, sharp curette. RESULTS: A total of 46 patients (32 females and 14 males, mean age 39.9 ± 5.7 years) with SH skin lesions varying in severity were included in this study. The mean time of repair was 11.5 ± 1.9 days; a shorter repair time was seen in females and for mild extension lesions (p < 0.001). A fair cosmetic outcome was seen in 76.1% of cases, with better results reported for females and for skin types II and III (p < 0.001). CONCLUSIONS: The method reported herein is an easy, rapid, and effective procedure for the complete removal of SH lesions with few complications in the majority of patients with numerous lesions and Fitzpatrick skin types II-IV. Cosmetic outcomes are better in females and skin types II and III.


Subject(s)
Curettage/methods , Facial Dermatoses/therapy , Laser Therapy/methods , Sebaceous Glands/pathology , Skin Diseases/therapy , Adult , Cohort Studies , Combined Modality Therapy/methods , Esthetics , Facial Dermatoses/pathology , Female , Follow-Up Studies , Humans , Hyperplasia/pathology , Hyperplasia/therapy , Lasers, Gas/therapeutic use , Male , Middle Aged , Prospective Studies , Risk Assessment , Severity of Illness Index , Skin Diseases/pathology , Treatment Outcome
20.
J Mol Cell Cardiol ; 128: 134-144, 2019 03.
Article in English | MEDLINE | ID: mdl-30716327

ABSTRACT

OBJECTIVE: The high rate of vein graft failure due to neointimal hyperplasia is a major challenge for cardiovascular surgery. Finding novel approaches to prevent neointimal hyperplasia is important. Thus, the purpose of this study was to investigate whether dedicator of cytokinesis 2 (DOCK2) plays a role in the development of neointima formation in the vein grafts. METHODS AND RESULTS: We found that DOCK2 levels were significantly elevated in the vein grafts following grafting surgery. In addition, overexpression of DOCK2 promoted venous smooth muscle cell (SMC) proliferation and migration. Conversely, knocking-down endogenous DOCK2 expression in venous SMCs inhibited SMC proliferation and migration. Consistent with this, knocking-down DOCK2 expression in the grafted veins significantly reduced neointimal formation compared with the controls 28 days after vein transplantation. Moreover, DOCK2 silencing treatment improved hemodynamics in the vein grafts. Mechanistically, knockdown of DOCK2 significantly alleviated the vein graft-induced down regulation of SMC contractile protein expression and impeded the vein graft-induction of both Cyclin D1 and PCNA expression. In particular, to ensure high efficiency when transferring the DOCK2 short hairpin RNA (shDOCK2) into the grafted veins, a 30% poloxamer F-127 gel incorporated with 0.25% trypsin was smeared around the vein grafts to increase the adenovirus contact time and penetration. CONCLUSIONS: DOCK2 silencing gene therapy effectively attenuates neointimal hyperplasia in vein grafts. Knock-down of DOCK2 would be a potential therapeutic approach for the treatment of vein graft failure.


Subject(s)
Cardiovascular Surgical Procedures/adverse effects , Graft Rejection/genetics , Guanine Nucleotide Exchange Factors/genetics , Transplants/growth & development , Veins/growth & development , Animals , Cyclin D1/genetics , Gene Expression Regulation, Developmental/drug effects , Graft Rejection/pathology , Graft Rejection/therapy , Guanine Nucleotide Exchange Factors/antagonists & inhibitors , Humans , Hyperplasia/metabolism , Hyperplasia/pathology , Hyperplasia/therapy , Myocytes, Smooth Muscle/metabolism , Myocytes, Smooth Muscle/pathology , Neointima/genetics , Neointima/pathology , Poloxamer/pharmacology , Proliferating Cell Nuclear Antigen/genetics , Rats , Transplants/pathology , Veins/drug effects , Veins/surgery
SELECTION OF CITATIONS
SEARCH DETAIL